VISIPAQUE 320 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Visipaque 320, and what generic alternatives are available?
Visipaque 320 is a drug marketed by Ge Healthcare and is included in two NDAs.
The generic ingredient in VISIPAQUE 320 is iodixanol. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the iodixanol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Visipaque 320
A generic version of VISIPAQUE 320 was approved as iodixanol by HENGRUI PHARMA on May 19th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VISIPAQUE 320?
- What are the global sales for VISIPAQUE 320?
- What is Average Wholesale Price for VISIPAQUE 320?
Summary for VISIPAQUE 320
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Clinical Trials: | 31 |
| Patent Applications: | 3,960 |
| DailyMed Link: | VISIPAQUE 320 at DailyMed |
Recent Clinical Trials for VISIPAQUE 320
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institute of Liver and Biliary Sciences, India | N/A |
| University of Washington | Phase 1 |
| Guerbet | Phase 1 |
Pharmacology for VISIPAQUE 320
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for VISIPAQUE 320
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020351-002 | Mar 22, 1996 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020808-002 | Aug 29, 1997 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VISIPAQUE 320
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020351-002 | Mar 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020351-002 | Mar 22, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020808-002 | Aug 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020808-002 | Aug 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020808-002 | Aug 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020808-002 | Aug 29, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VISIPAQUE 320
See the table below for patents covering VISIPAQUE 320 around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 950010 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 9011094 | ⤷ Sign Up | |
| Ireland | 48437 | A PROCESS FOR THE PREPARATION OF A STERILE INJECTABLE PHYSIOLOGICALLY ACCEPTABLE SOLUTION OF AN X-RAY CONTRAST AGENT AND SOLUTIONS OF THE X-RAY CONTRAST AGENT AND A BUFFER | ⤷ Sign Up |
| Italy | 1193761 | PROCEDIMENTO PER PREPARARE UNA SOLUZIONE STERILE STABILE DI UN AGENTE DI COTRASTO PER RAGGI X | ⤷ Sign Up |
| Netherlands | 183121 | ⤷ Sign Up | |
| Slovakia | 278621 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VISIPAQUE 320
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0108638 | 97C0101 | Belgium | ⤷ Sign Up | PRODUCT NAME: IODIXANOL; NAT. REGISTRATION NO/DATE: 914 IS 204 F 12 19970325; FIRST REGISTRATION: SE 11758 19930205 |
| 0108638 | SPC/GB93/150 | United Kingdom | ⤷ Sign Up | SPC/GB93/150, 20031107, EXPIRES: 20080330 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
